Data / Drug companies / Armas Pharmaceuticals Inc.
Armas Pharmaceuticals Inc.: 68 products in the FDA NDC directory, labeler code 72485
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Armas Pharmaceuticals Inc. (labeler code 72485) lists 68 products in the FDA National Drug Code Directory, covering 44 finished drugs by generic name. By type: 67 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 21, 2026.
The request: Watch Armas Pharmaceuticals Inc. (FDA labeler code 72485): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72485
- Products in commercial distribution
- 68
- Packages
- 87
- Finished drugs by generic name
- 44
- Prescription products
- 67
- Over the counter products
- 1
- Flagged as original packager
- 63 of 63 products that carry the flag
- Started marketing in the last 12 months
- 11
- Earliest marketing start
- September 10, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 68 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 67 | 98.5% |
| Over the counter drugs | 1 | 1.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 19 | 27.9% |
| Injection, solution | 15 | 22.1% |
| Injection, powder, for solution | 11 | 16.2% |
| Tablet, film coated | 7 | 10.3% |
| Injection, powder, lyophilized, for solution | 4 | 5.9% |
| Solution/ drops | 4 | 5.9% |
| Suspension/ drops | 3 | 4.4% |
| Solution | 2 | 2.9% |
| Jelly | 1 | 1.5% |
| Gel | 1 | 1.5% |
| Ointment | 1 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ziprasidone Mesylate 20 mg/mL | 72485-430 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 21, 2026 |
| Carboprost Tromethamine | 72485-525 | Injection, solution | Generic drugs (ANDA) | September 15, 2026 |
| Labetalol Hydrochloride | 72485-515 | Injection, solution | Generic drugs (ANDA) | September 15, 2026 |
| Erythromycin Lactobionate | 72485-701 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 9, 2026 |
| Desmopressin Acetate | 72485-524 | Injection, solution | Generic drugs (ANDA) | June 30, 2026 |
| Desmopressin Acetate | 72485-523 | Injection, solution | Generic drugs (ANDA) | June 30, 2026 |
| Ropivacaine Hydrochloride | 72485-519 | Injection | Generic drugs (ANDA) | June 1, 2026 |
| Sumatriptan | 72485-518 | Injection, solution | Generic drugs (ANDA) | June 1, 2026 |
| Haloperidol Decanoate | 72485-522 | Injection | Generic drugs (ANDA) | May 15, 2026 |
| Haloperidol Decanoate | 72485-521 | Injection | Generic drugs (ANDA) | May 15, 2026 |
| Haloperidol Decanoate | 72485-520 | Injection | Generic drugs (ANDA) | May 15, 2026 |
| Ampicillin | 72485-423 | Injection, powder, for solution | Generic drugs (ANDA) | May 1, 2025 |
| Ampicillin Sodium and Sulbactam Sodium | 72485-418 | Injection, powder, for solution | Generic drugs (ANDA) | May 1, 2025 |
| Dexamethasone Sodium Phosphate | 72485-118 | Injection, solution | Generic drugs (ANDA) | April 22, 2025 |
| Lidocaine | 72485-611 | Jelly | Generic drugs (ANDA) | March 2, 2025 |
| Cisatracurium Besylate | 72485-513 | Injection | Generic drugs (ANDA) | January 15, 2025 |
| Nicardipine Hydrochloride | 72485-116 | Injection | Generic drugs (ANDA) | April 3, 2024 |
| Tranexamic Acid | 72485-510 | Injection | Generic drugs (ANDA) | February 6, 2024 |
| Etomidate | 72485-509 | Injection, solution | Generic drugs (ANDA) | January 22, 2024 |
| Etomidate | 72485-508 | Injection, solution | Generic drugs (ANDA) | January 22, 2024 |
| Ampicillin | 72485-421 | Injection, powder, for solution | Generic drugs (ANDA) | November 10, 2023 |
| Brimonidine Tartrate/Timolol Maleate | 72485-634 | Solution/ drops | Generic drugs (ANDA) | November 3, 2023 |
| Ciprofloxacin and dexamethasone | 72485-625 | Suspension/ drops | Generic drugs (ANDA) | November 1, 2023 |
| Nafcillin sodium | 72485-406 | Injection, powder, for solution | Generic drugs (ANDA) | November 1, 2023 |
| Nafcillin sodium | 72485-405 | Injection, powder, for solution | Generic drugs (ANDA) | November 1, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.